We are live on ! Find out more

VanEck Biotech ETF

BBH

Market cap $523M

256.80 USD

+2.30

0.9%

At close Updated Nov 3, 1:26 PM EST

1 day

0.9%

5 days

3.44%

1 month

6.76%

3 months

25.71%

6 months

38.35%

Year to date

34.99%

1 year

42.64%

5 years

26.58%

10 years

157.31%

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 72.7%

Neutral 27.3%

Negative 0%

Zacks Investment Research

ETFs That You May Consider Amid a Strengthening Biotech Outlook

Drug innovation, AI and rising M&A activity are boosting biotech optimism. Discover ETFs offering exposure to the sector.

ETFs That You May Consider Amid a Strengthening Biotech Outlook

Zacks Investment Research

Why Healthcare ETFs Are Hovering Around One-Year Highs

Healthcare ETFs are hovering near 52-week highs as earnings prospects improve, clinical breakthroughs advance and GLP-1 demand expands. Explore five ETFs riding the rally.

Why Healthcare ETFs Are Hovering Around One-Year Highs

Zacks Investment Research

Biotech ETF (BBH) Hits New 52-Week High

For investors seeking momentum, VanEck Biotech ETF BBH is probably on the radar. The fund just hit a 52-week high and has risen 41.1% from its 52-week low price of $176.30/share.

Biotech ETF (BBH) Hits New 52-Week High

The Motley Fool

Better Biotechnology ETF: First Trust FBT vs. VanEck BBH

The First Trust NYSE Arca Biotechnology Index Fund has outperformed the VanEck Biotech ETF on a one-year basis and over the last five years. The VanEck Biotech ETF offers a lower expense ratio of 0.35% compared to 0.55% for the First Trust fund.

Better Biotechnology ETF: First Trust FBT vs. VanEck BBH

The Motley Fool

Fidelity Healthcare ETF (FHLC) vs. VanEck Biotech ETF (BBH): Which Fund Is the Better Buy?

FHLC features a much lower expense ratio of 0.08% compared to 0.35% for BBH. BBH is a concentrated portfolio of just 26 stocks, while FHLC holds around 350 companies.

Fidelity Healthcare ETF (FHLC) vs. VanEck Biotech ETF (BBH): Which Fund Is the Better Buy?

Zacks Investment Research

Biotech ETFs to Buy as Cancer Drug Breakthroughs Accelerate

Biotech ETFs offer diversified exposure to oncology innovation as cancer funding surges and the global oncology drug market expands.

Biotech ETFs to Buy as Cancer Drug Breakthroughs Accelerate

Retension Pharmaceuticals, TRex Bio file for US IPO as biotech momentum continues

Drug developers Retension Pharmaceuticals and TRex Bio filed their paperwork for U.S. initial public offerings on Friday, reinforcing the biotech pipeline for the fall IPO window.

Retension Pharmaceuticals, TRex Bio file for US IPO as biotech momentum continues

5 Undervalued Oncology Stocks Wall Street Is Overlooking

Oncology spending is projected to reach $441 billion by 2029, but market growth is expected to slow as established therapies face generic and biosimilar competition. Several oncology blockbusters are also approaching loss of exclusivity, including Pfizer's Ibrance in 2027–2028 and Bristol Myers Squibb's Opdivo in 2028–2030. Overall, the oncology rally has been broad, but I believe several underappreciated companies still offer meaningful upside.

5 Undervalued Oncology Stocks Wall Street Is Overlooking

Zacks Investment Research

Should You Invest in the VanEck Biotech ETF (BBH)?

Looking for broad exposure to the Healthcare - Biotech segment of the equity market? You should consider the VanEck Biotech ETF (BBH), a passively managed exchange traded fund launched on December 20, 2011.

Should You Invest in the VanEck Biotech ETF (BBH)?

BBH: Biotech's Next Growth Cycle Is Just Getting Started

VanEck Biotech ETF (BBH) is a Buy, offering concentrated exposure to leading biotech firms entering a new growth cycle. BBH's top holdings—Amgen, Gilead, and Vertex—drive capital appreciation through diversified pipelines, strong cash flows, and expansion into new therapeutic areas. Despite a higher expense ratio and low yield, BBH's risk-reward profile is attractive given enduring demand and robust product pipelines.

BBH: Biotech's Next Growth Cycle Is Just Getting Started

See News Rankings

Price charts implemented using Lightweight Charts™